Premier stated it has submitted comments in response to the DEA’s proposed reduction in quotas for 2021.
DEA proposes reducing the aggregate production quotas (APQs) for several schedule II-controlled substances for the fifth year in a row including:
· Fentanyl – 18 percent reduction
· Hydromorphone – eight percent reduction
· Oxycodone – 16 percent reduction
Given the ongoing prevalence of COVID-19 cases throughout the country, and an anticipated resurgence of the disease in the fall and winter, Premier is concerned that reducing APQs for these critical medications needed to treat COVID-19 patients may be premature and may inadvertently lead to further shortages.
Prior to finalization of the 2021 quotas, Premier cautions the DEA to carefully consider how a reduction in manufacturing quotas for certain opioids at this time could exacerbate recent drug shortages for injectable opioids and have a negative effect on preparedness and readiness for a resurgence of COVID-19 cases. In addition, Premier urges DEA to consider increased demand in 2021 due to federal and state stockpiling requirements that are in the process of being implemented.
